# Liste modèle des médicaments essentiels

## Abacavir

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Oral > Solid: 300 mg tablet (as sulfate) | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |

## Didanosine

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution<br>◦ Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |

## Emtricitabine

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Oral > Liquid: 10 mg per mL<br>◦ Oral > Solid: 200 mg | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |

## Lamivudine

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Oral > Liquid: 50 mg per 5 mL<br>◦ Oral > Solid: 150 mg tablet | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |

## Stavudine

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Oral > Liquid: 5 mg per 5 mL powder for oral solution<br>◦ Oral > Solid: 15 mg; 20 mg; 30 mg | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |

## Tenofovir disoproxil fumarate

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil) | Contact with or exposure to human immunodeficiency virus<br>Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |

## Zidovudine

| Section | Indications |
| --- | --- |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>◦ Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion<br>◦ Oral > Liquid: 50 mg per 5 mL<br>◦ Oral > Solid > tablet: 300 mg<br>◦ Oral > Solid > capsule: 250 mg | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified |